- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
PLAY BUTTON
PLAY BUTTON
236 Cards in this Set
- Front
- Back
|
Lymphocyte population that is most responsible for the clearance of extracellular microbes.
|
B cells
|
|
Lymphocyte population that is most responsible for the clearance of intracellular microbes.
|
T cells
|
|
Active immunity that is naturally acquired.
|
Recovery from infection
|
|
Active immunity that is artificially acquired.
|
Vaccination
|
|
Passive immunity that is naturally acquired.
|
Placental transfer of antibody (IgG)
|
|
Passive immunity that is artificially acquired.
|
Injection of immune globulin
|
|
Maturation stage of a mature lymphocyte that is long-lived and read to rapidly respond to antigen on the second/subsequent exposures.
|
Memory lymphocyte
|
|
Secondary lymphoid tissue where the response occurs to blood-borne antigens.
|
Spleen
|
|
Secondary lymphoid tissue where the response occurs to tissue-borne antigens.
|
Lymph nodes, MALT, GALT, BALT
|
|
Anatomic site of B cell maturation
|
Bone marrow
|
|
Professional antigen presenting cells
|
Dendritic cells, macrophages, B cells, FDC
|
|
Anatomic location of T cells in lymph nodes
|
Paracortex
|
|
Anatomic location of B cells in lymph nodes
|
Follicle
|
|
Anatomic location of T cells in spleen
|
Periarteriolar sheath
|
|
Cellular receptors for microbial antigens found on innate immune cells
|
Toll-like receptors
|
|
Neutrophils, macrophages, dendritic cells, B cells
|
Phagocytic cells
|
|
Lysozyme, reactive oxygen intermediates, nitric oxide
|
Microbicidal molecules of phagocytes
|
|
Enzyme that induces reactive oxygen species
|
Phagocyte oxidase
|
|
Pro-inflammatory cytokines that target endothelium
|
TNF, IL-1
|
|
Adhesion molecules expressed on endothelium that mediate rolling of leukocytes
|
E and P Selectins
|
|
Adhesion molecules expressed on leukocytes that mediate tethering of leukocytes
|
Integrins
|
|
Lymphocytes of innate immunity that provide early defense against viral infections
|
NK cells
|
|
Major source of IFN in innate immune system
|
NK cells
|
|
Structural domains found on inhibitory receptors of NK cells
|
ITIMs
|
|
Structural domains found on activating receptors of NK cells
|
ITAMs
|
|
Intraepithelial lymphocytes that are early sentinels of bacterial infections
|
gd T cells
|
|
Activates classical pathway of complement
|
Antibody binding to C1q
|
|
Activates alternative pathway of complement
|
Binding of C3b to microbial surfaces
|
|
Activates lectin pathway of complement
|
Terminal mannose residues of microbial glycoproteins
|
|
Major opsonin generated by complement activation
|
C3b
|
|
Pro-inflammatory molecules generated by complement activation
|
C3a and C5a
|
|
Cytokines that activate endothelium
|
TNF and IL-1
|
|
Class of cytokines that increase integrin affinity and are chemotacic
|
Chemokines
|
|
Cytokine that induces IFN production by NK cells and T cells
|
IL-12
|
|
Cytokine that down-regulates immune responses
|
IL-10
|
|
Inducers of the acute phase response
|
TNF, IL-1, IL-6
|
|
Induces proliferation of plasma cells
|
IL-6
|
|
C-reactive protein, mannose-binding lectin and others
|
Acute phase proteins
|
|
Signals generated by innate immune response to stimulate lymphocytes
|
B7, C3d and IL-12
|
|
Substances given with vaccines that stimulate immune responses
|
Adjuvants
|
|
Recognition by T cells of peptides bound to one’s own MHC molecules
|
MHC restriction
|
|
Professional APC’s
|
Dendritic cells, macrophages, B cells
|
|
Another name for immature dendritic cell in the skin
|
Langerhans cell
|
|
Microbial-induced activators of dendritic cells
|
TNF, IL-1, TLR signaling
|
|
Location of dendritic cells in secondary lymphoid tissue
|
Cortical T cell areas
|
|
Chemical signal that attracts activated dendritic cells to draining lymph node
|
Chemokines that bind to CCR7 on dendritic cell
|
|
Name the molecules that encode the Class I MHC molecules
|
A, B, C
|
|
Name the cells that express Class I MHC molecules
|
All nucleated cells
|
|
Name the molecules that encode the Class II MHC molecules
|
DP, DQ, and DP
|
|
Name the cells that express Class II MHC molecules
|
Professional APC’s
|
|
Domains of peptide-binding groove of MHC Class I molecules
|
1: 2
|
|
CD8 binding site of MHC Class I molecule
|
3
|
|
Domains of peptide-binding groove of MHC Class II molecules
|
1:1
|
|
CD4 binding site of MHC Class II molecule
|
2
|
|
Source of antigens for MHC Class I molecules
|
Endogenous cytosolic proteins
|
|
Source of antigens for MHC Class II molecules
|
Endosomes/Lysosomes
|
|
Site of peptide loading for MHC Class I molecule
|
Endoplasmic reticulum
|
|
Site of peptide loading for MHC Class II molecule
|
Vesicle
|
|
Enzymes that generate peptides for MHC Class I molecules
|
Proteosome
|
|
Enzymes that generate peptides for MHC Class II molecules
|
Proteases in vesicles
|
|
Main determinates of organ rejection
|
MHC II
|
|
Antigen-binding domains of a B cell receptor (BCR)
|
VH: VL
|
|
Predominant version of T cell receptor in adaptive immunity
|
aB- receptor
|
|
Antigen-binding domains of the T cell receptor (TCR)
|
Va: Vb
|
|
Signaling molecules of BCR complex
|
Ig-alpha and Ig-beta
|
|
Signaling molecules of TCR complex
|
CD3 and zeta
|
|
Portion of Ig molecule that binds complement
|
Fc
|
|
Number of antigen binding sites on the TCR
|
One
|
|
Antibody found in GI tract, colostrum, sweat, tears, saliva
|
Dimeric IgA
|
|
M.C. form IgM
|
pentameric
|
|
Fixes complement but does not cross placenta
|
IgM
|
|
Lowest conc Ig in serum
|
IgE
|
|
Idiotype epitopes
|
hypervariable region is unique
|
|
Major class of antibody directed at helminth infections
|
IgE
|
|
Classes of antibody that serve as BCR on naive B cells
|
IgD and IgM
|
|
Opsonizing antibodies
|
IgG and IgA
|
|
Half-life of IgG
|
21 days
|
|
Portion of Ig molecule that determines isotype
|
Heavy chains
|
|
First recombination event in BCR heavy chain and TCR chain
|
D-J joining
|
|
Change of Ig class but preservation of antigen specificity
|
Isotype or class switching
|
|
Nucleotide changes in variable regions of Ig genes affecting affinity for antigen
|
Somatic hypermutation
|
|
Enzymes responsible for somatic recombination
|
VDJ recombinase (RAG-1 and RAG-2)
|
|
Number of CDR’s in an intact TCR
|
Six
|
|
Total number of V-(D)-J combinations
|
Combinatorial diversity
|
|
Number of CDR’s in an intact BCR
|
Six
|
|
Stage of B cell with no detectable recombination events
|
Pro-B cell
|
|
Stage of B cell with recombined H chain and RNA and surrogate light chains
|
Pre-B cell
|
|
Stage of B cell with IgM expressed on surface
|
Immature B cell
|
|
Stage of B cell with IgM and IgD expressed on surface
|
Mature B cell
|
|
Stage of T cell with no recombined chain
|
Double negative thymocyte; Pro-T cell
|
|
Stage of T cell with recombined chain and expressed pre-T
|
Pre-T cell
|
|
Stage of T cell with expressed TCR and both CD4 and CD8
|
Double-positive T cell; immature T cell
|
|
No recognition of MHC + self-peptide
|
Failure of positive selection
|
|
Strong recognition of MHC + peptide
|
Negative selection
|
|
Location of most intracellular pathogens that have invaded cells
|
Cytoplasm
|
|
T cell accessory molecule that binds co-stimulators
|
CD28
|
|
T cell accessory molecule involved in negative regulation of activated T cells
|
CTLA-4
|
|
APC molecule that provides second signal to T cells
|
B7
|
|
T cell accessory molecules involved in adhesion
|
LFA-1 and VLA-4
|
|
Substances that induce expression of co-stimulators on APCs
|
Adjuvants
|
|
Autocrine cytokine that promotes T cell proliferation
|
IL-2
|
|
Region of contact between APC and T cell
|
Immunologic synapse
|
|
Anatomical site of activation of T cells by APCs
|
Paracortex of lymph nodes
|
|
Tyrosine motifs on CD3 and chains involved in signaling
|
ITAMs
|
|
Tyrosine kinase that triggers several signaling pathways
|
ZAP-70
|
|
High affinity version of the IL-2 Receptor
|
IL-2R-alpha-beta-gamma-c
|
|
T cell population that defends against intracellular microbes
|
Th1
|
|
Cytokines that drive development of Th1 cells
|
IL-12, IFN
|
|
Signature cytokines of Th1cells
|
Interferon-gamma, TNF, IL-2
|
|
T cell population that defends against extracellular microbes
|
Th2
|
|
Cytokine that drives development of Th2 cells
|
IL-4
|
|
Signature cytokines of Th2 cells
|
IL4, IL-5, IL-13
|
|
T cell population involved in inflammatory disorders
|
Th17
|
|
Cytokine that inhibits T cell activation
|
TGF-alpha
|
|
Cytokine that induces B cell switching to produce IgE
|
IL-4
|
|
Cytokine that activates eosinophils
|
IL-5
|
|
T cell population that drives activation of macrophages and production of some classes of antibodies
|
Th1
|
|
T cell population that drives production of some classes of antibodies
|
Th2
|
|
T cell population that directly kills infected cells
|
CTLs
|
|
Ligand expressed on CD4+ T cells that makes APC better at stimulating T cells
|
CD40L
|
|
Defense against ingested microbes
|
Th1 cells
|
|
Anatomical site of activation of naive T cells
|
Lymphoid organs
|
|
Anatomical site of antigen elimination by effector T cells
|
Peripheral tissues
|
|
Effector cell of delayed-type hypersensitivity (DTH)
|
Macrophage
|
|
Time frame to elicit a DTH reaction
|
24-48 hours
|
|
Chronic CMI response to TB
|
granulomas
|
|
Defense against helminth infections
|
IgE and Il-5-activated eosinophils
|
|
Enzymes that cleave and activate caspases
|
Granzymes
|
|
Protein necessary for delivery of granzymes into target cells
|
Perforin
|
|
Mechanism of CTL-mediated killing of target cell
|
Apoptosis
|
|
Cytokines that inhibit microbicidal activity of macrophages
|
IL-4, IL-10, IL-13
|
|
Viral-induced mechanism of immune evasion
|
Inhibit antigen presentation
|
|
Mycobacteria-induced mechanism of immune evasion
|
Inhibit phagolysosome fusion
|
|
B cell population that resides in follicles of lymph nodes
|
Follicular B cells
|
|
B cell population that resides in marginal zones of spleen
|
Marginal zone B (MZB) cells
|
|
B cell populations that produce primarily IgM
|
MZB cells and B-1 B cells
|
|
Components of B cell antigen receptor complex
|
BCR; Ig-alpha, Ig-beta
|
|
Ligand for CR2
|
C3d (and iC3b)
|
|
Anatomical site of activation of naive B cells
|
B cell zones of lymphoid tissues
|
|
Mechanism of helper T cell-induced activation of B cells
|
CD40L and cytokines
|
|
Effector mechanism of B cells in humoral immunity
|
Secretion of antibodies
|
|
Inducers of heavy chain isotype switching
|
CD40L and cytokines
|
|
Basis of X-linked hyper-IgM syndrome
|
Defective CD40L
|
|
Major cytokine that induces switching to IgG
|
IFN-gamma
|
|
Major cytokine that induces switching to IgE
|
IL-4
|
|
Major cytokine that induces switching to IgA
|
TGF-beta
|
|
Anatomical site where affinity maturation occurs
|
Germinal centers of lymphoid follicles
|
|
This type of antigen only induces an IgM response
|
T-independent antigens
|
|
This type of antigen results in isotype switching
|
T-dependent antigens
|
|
Receptor that mediates antibody feedback
|
Fc-gamma-RII receptor
|
|
Most important antibody for complement activation
|
IgM > IgG
|
|
Neutralizing antibody
|
IgG, IgA
|
|
NK cell-mediated killing of IgG-coated cells
|
Antibody-dependent cellular cytotoxicity (ADCC)
|
|
Fc receptor involved in ADCC
|
Fc-gamma-RIII (CD16)
|
|
Fc receptor involved mast cell degranulation
|
Fc-E-RI
|
|
Fc receptor involved in down-regulation of B cell activity
|
Fc-gamma-RIIB (CD32)
|
|
Fc receptor involved in transporting IgG from blood to extracellular spaces
|
FcRn
|
|
C3 convertase of classical pathway
|
C4b2b
|
|
Complement products that are chemotactic
|
C5a > C3a, C4a,
|
|
C3 convertase of alternative pathway
|
C3bBb
|
|
C5 convertase of classical pathway
|
C4b2b3b
|
|
C5 convertase of alternative pathway
|
C3bBbC3b
|
|
Component of MAC that polymerizes
|
C9
|
|
Deficiency of this complement regulatory protein results in Hereditary Angioneurotic Edema
|
C1 inhibitor
|
|
Proteins unique to the alternative pathway of complement
|
Properdin, Factor B and D
|
|
Type of immune protection from bacterial vaccines
|
Antibodies
|
|
Type of immune protection from live attenuated viral vaccines
|
Antibodies and CMI
|
|
Mechanism of immune evasion by altering surface antigens recognized by immune system
|
Antigenic variation
|
|
Tolerance induced in primary lymphoid organs
|
Central tolerance
|
|
Tolerance induced in peripheral tissues
|
Peripheral tolerance
|
|
Apoptosis of immature lymphocytes due to strong interaction with self peptides
|
Negative selection/deletion
|
|
T cell population that arises from recognition of self-antigen
|
Regulatory T cells
|
|
Functional inactivation of T cells when exposed to antigen without co-stimulation
|
Anergy
|
|
Inhibitory receptors that maintain inactivity of autoreactive T cells
|
CTLA-4
|
|
Apoptosis of mature lymphocytes that recognize self peptides
|
Deletion/activation-induced cell death
|
|
Mechanisms of apoptosis in activation-induced cell death
|
Pro-apoptotic proteins or Fas-FasL interaction
|
|
Chance of autoimmunity in individual who inherits a particular HLA allele compared with one who does not
|
Relative risk
|
|
Defect in these serum proteins results in lupus-like disease
|
C2 & C4
|
|
Defect in these genes results in autoimmune lymphoproliferative syndrome
|
Fas/FasL
|
|
Types of antigens that activate large numbers of T cells without binding to antigen recognition site of the TCR
|
Superantigens
|
|
Tissues/organs normally sequestered from immune response
|
Eye, testes, ovary
|
|
Type of antigen typically presented to lymphocytes without second signals
|
Tolerogenic self antigens
|
|
Type of antigen typically present in peripheral lymphoid tissue
|
Immunogenic foreign antigens
|
|
Type of antigen typically presented to lymphocytes with second signals
|
Immunogenic foreign antigens
|
|
Route of administration of an antigen most likely to induce tolerance
|
Orally
|
|
Route of administration of an antigen most likely to induce an immune response
|
Subcutaneous or intramuscular
|
|
Failure to produce tumor antigens
|
Mechanism of tumor evasion
|
|
Mutations in MHC genes or genes needed for antigen processing
|
Mechanism of tumor evasion
|
|
Grafts from identical animals
|
Syngeneic
|
|
Grafts from animals of the same species
|
Allogeneic
|
|
Grafts from animals that are from different species
|
Xenogeneic
|
|
Recipient T cells recognize processed donor alloantigens
|
Indirect recognition
|
|
Graft rejection mediated by preformed antibodies that occurs in minutes
|
Hyperacute
|
|
Graft rejection mediated by T cells and/or antibodies that occurs within days or weeks
|
Acute
|
|
Graft rejection characterized by complement activation, endothelial damage, inflammation and thrombosis
|
Hyperacute
|
|
Graft rejection characterized by parenchymal cell damage, interstitial inflammation and inflammation of the endothelium
|
Acute
|
|
Drug that inhibits macrophage cytokine secretion
|
Glucocorticoids
|
|
Biologic agent that depletes T cells by promoting phagocytosis or complement-mediated lysis
|
Anti-CD3 monoclonal antibody
|
|
Biologic agent that inhibits T cell proliferation
|
Anti-IL-2R antibody
|
|
Type I hypersensitivity
|
Th2 cells, IgE, mast cells, eosinophils
|
|
Type II hypersensitivity
|
IgM, IgG vs. cell surface or extracellular matrix
|
|
Type III hypersensitivity
|
Circulating Ag-Ab (IgG or IgM) complexes (soluble antigens)
|
|
Mast-cell derived mediators; cytokine-mediated inflammation
|
Mechanisms of tissue injury in Type I
|
|
Complement and FcR-mediated recruitment and activation of leukocytes; Opsonization, phagocytosis; Abnormal cell function
|
Mechanisms of tissue injury in Type II
|
|
Complement and FcR-mediated recruitment and activation of leukocytes
|
Mechanisms of tissue injury in Type III
|
|
Macrophage activation; direct target cell killing; cytokine-mediated inflammation
|
Mechanisms of tissue injury in Type IV
|
|
Cross-linking of allergen with two or more IgE molecules on surface of mast cell
|
Induce mast cell degranulation
|
|
Contents of mast cell granules
|
Vasoactive amines, proteases
|
|
Mediators of late phase of allergic response
|
Cytokines (TNF, IL-4), platelet activating factor and Leukotrienes
|
|
Leukocytes involved in late phase of allergic reaction
|
Eosinophils, neutrophils, Th2 cells
|
|
This treatment for allergies induces B cells to switch from IgE to other isotypes
|
Desensitization
|
|
Antibody-mediated disease that damages the heart due to inflammation and macrophage activation
|
Acute rheumatic fever
|
|
Antibody-mediated disease that destroys platelets via opsonization an phagocytosis
|
Autoimmune thrombocytopenic purpura
|
|
Antibody-mediated disease that damages the kidneys due to complement and FcR-mediated inflammation
|
Goodpasture’s syndrome
|
|
Microbial proteins that induce polyclonal T cell activation which results in toxic shock syndrome
|
Superantigens
|
|
Deficiencies in this immune compartment lead to pyogenic bacterial infections
|
B cell deficiencies
|
|
Deficiencies in this immune compartment lead to variable types of infection depending on specific defect
|
Innate immune deficiencies
|
|
Lack of B and T cell-mediated immune responses
|
SCID
|
|
Immunologic consequence of abnormal development of 3rd and 4th branchial pouches
|
Thymic hypoplasia
|
|
Disease marked by lack of CMI due to thymic hypoplasia
|
DiGeorge Syndrome
|
|
Disease marked by elevated levels of IgM, decreased levels of other antibody classes and decreased CMI
|
X-linked hyper-IgM syndrome
|
|
Selective deficiency of IgG, IgA and or IgM due to defects in heavy chains
|
Common variable immunodeficiency
|
|
Defective T cell responses due to abnormal antigen processing
|
Bare lymphocyte syndrome
|
|
Disease with defective microbicidal killing by phagocytes due to mutation in phagocyte oxidase
|
Chronic granulomatous disease
|
|
Laboratory test that detects defective phagocyte killing
|
Nitroblue tetrazolium test
|
|
Disease with recurrent bacterial infections due to defective lysosomal function
|
Chediak-Higashi
|
|
Disease where defective cytoskeleton components leads to abnormally small platelets and leukocytes
|
Wiskott Aldrich syndrome
|
|
Immunologic consequence of C2 and/or C4 deficiency
|
Failure to clear immune complexes
|
|
Small molecule that can not induce an immune response
|
Hapten
|
|
Antibody that reacts with a single epitope
|
Monoclonal antibody
|
|
Strength of interaction between one antibody and its antigen
|
Affinity
|
|
Sum of the strengths of multivalent antigens with all of the antibodies that bind to that antigen
|
Avidiity
|
|
Reaction of an antibody with a cell or particle
|
Agglutination
|
|
Hemagglutination test used to detect the presence of anti-Rh antibodies
|
Coomb’s test
|
|
Aggregation of an insoluble particle by an antibody
|
Flocculation
|
|
Concentration of antibody in a serum sample
|
Titer
|
